Nanoscale detection of ovarian cancer biomarker

Marwah Al-ogaidi; Nuha Nihad A. Aburahma; Ansam M. Salman; Haider Raad

Nanoscale detection of ovarian cancer biomarker

Abstract

It is estimated that over 2,000 women globally are impacted by ovarian cancer (OC). Unfortunately, every year, over half of the cases end in death. This underscores the critical importance of better early detection and diagnosis of OC. Research into improving a sensitive, dependable, and rapid cancer serum antigen (CA-125) detector is essential for medical diagnosis. This antigen may signal the earliest stages of ovarian cancer. The typical crystalline size of the Cadmium selenide (CdSe) quantum dots (QDs) that we synthesized and coated is adjusted in this study to be 8 ± 0.2 nm. Multiple characterization methods, including X-ray diffraction, Z-scan, and transmission electron microscopy, were utilized to verify their properties. We used these QDs as optical tags for a sandwich assay, which was used to test a high-binding surface where the capture antibody was immobilized. Popular optical tags (QDs), semiconductor nanoparticles with size-dependent fluorescence spectra, brightness, and photostability, were used and can be detected by a microplate spectrophotometer. A linear curve was observed within a range of 5–1000 U/ml CA-125, which is suitable for quantitative work, and the detection limit was 4.5 U/ml. The interference with the detection of CA-125 was tested in human serum, and the results showed no significant difference in the fluorescence spectra. Third-order nonlinear optical parameter analysis of conjugated CdSe QDs under an excitation beam power level of approximately 120 W and a wavelength of 532 nm was determined in detail. The third-order optical susceptibility (χ3) was 2.746 × 10-7 esu with a sound absorption coefficient of 4.68556 × 10-5 cm/W and nonlinear refractive index -5.6132 × 10-9 cm2/W. Finally, the resulting CdSe QDs have been effectively employed in the labeling and, hence, detection of ovarian cancer antigen (CA-125).

Keywords

References

REFERENCES
[1] Khazaei Z, Namayandeh SM, Beiranvand R, Naemi H, Bechashk SM, Goodarzi E. Worldwide incidence and mortality of ovarian cancer and Human Development Index (HDI): GLOBOCAN sources and methods 2018 J Prev Med Hyg 2021;62:E174.
[2] Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health 2019;11:287–299. [CrossRef]
[3] Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med 2017;14:9. [CrossRef]
[4] DiSaia PJ, Creasman WT, Mannel RS, McMeekin DS, Mutch DG. Clinical gynecologic oncology e-book. Elsevier Health Sciences; 2017.
[5] Elias KM, Guo J, Bast RC. Early detection of ovarian cancer. Hematol Clin 2018;32:903–914. [CrossRef]
[6] Nersesian S, Glazebrook H, Toulany J, Grantham SR, Boudreau JE. Naturally killing the silent killer: NK cell-based immunotherapy for ovarian cancer. Front Immunol 2019;10:1782. [CrossRef]
[7] Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol 2020;38:1222. [CrossRef]

[8] Zeff N. Role of laparoscopy in initial tumor staging in advanced epithelial ovarian cancer: a systematic review. Pleura Peritoneum 2018;3:20180106. [CrossRef]
[9] Landegren U, Hammond M. Cancer diagnostics based on plasma protein biomarkers: hard times but great expectations. Mol Oncol 2021;15:1715–1726. [CrossRef]
[10] Cvetkovic D. Early events in ovarian oncogenesis. Reprod Biol Endocrinol 2003;1:1–7. [CrossRef]
[11] Reiter MJ, Costello JE, Schwope RB, Lisanti CJ, Osswald MB. Review of commonly used serum tumor markers and their relevance for image interpretation. J Comput Assist Tomogr 2015;39:825–
834. [CrossRef]
[12] Gubbels JAA, Claussen N, Kapur AK, Connor JP, Patankar MS. The detection, treatment, and biology of epithelial ovarian cancer. J Ovarian Res 2010;3:1–11. [CrossRef]
[13] Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and ovarian cancer: a comprehensive review. Cancers (Basel) 2020;12:3730. [CrossRef]
[14] Twickler DM, Moschos E. Ultrasound and assessment of ovarian cancer risk. Am J Roentgenol 2010;194:322–329. [CrossRef] [15] Malati T. Tumour markers: an overview. Indian J Clin Biochem 2007;22:17–31. [CrossRef]
[16] National Cancer Institute. Cancer and Nanotechnology - NCI. 2022. Available at:
[17] Allayla AMT, Faris RA, Mahdi ZF. Construction of insulin-like growth factor nanocomposite biosensor by Raman spectroscopy. Vib Spectrosc 2021;114:103252. [CrossRef]
[18] Faris RA, Mahdi ZF, Husein MDA. Immobilised gold nanostructures on printing paper for label-free surface-enhanced Raman spectroscopy. IOP Conf Ser Mater Sci Eng 2020;871:12019. [CrossRef]
[19] Faris RA, Mahdi ZF, Al-Layla AMT. Preliminary study of the insulin growth factor binding protein-3 (IGFBP3) level in Iraqi women with breast cancer. AIP Conf Proc 2021;2372:30003. [CrossRef]
[20] Mahdi ZF, Faris RA, Sadeq ZS. Fast, sensitive and low-cost chemical sensor based on manufacturing nanostructured Co3O4 using Raman spectroscopy. Nano-Struct Nano-Obj 2021;28:100778. [CrossRef]
[21] Michalet X, Pinaud FF, Bentolila LA, Tsay JM, Doose S, Li JJ, et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005;307:538–544. [CrossRef]
[22] Gokarna A, Jin LH, Hwang JS, Cho YH, Lim YT, Chung BH, et al. Quantum dot-based protein micro-and nanoarrays for detection of prostate cancer biomarkers. Proteomics 2008;8:1809–1818. [CrossRef]
[23] Marchal F, Pic E, Pons T, Dubertret B, Bolotine L, Guillemin F. Quantum dots in oncological surgery: the future for surgical margin status? Bull Cancer 2008;95:1149–1153.
[24] Weng KC, Noble CO, Papahadjopoulos-Sternberg B, Chen FF, Drummond DC, Kirpotin DB, et al. Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett. 2008;8(9):2851–2857. [CrossRef]
[25] Zhou M, Ghosh I. Quantum dots and peptides: a bright future together. Pept Sci 2007;88:325–339. [CrossRef]
[26] Erogbogbo F, Yong KT, Roy I, Xu G, Prasad PN, Swihart MT. Biocompatible luminescent silicon quantum dots for imaging of cancer cells. ACS Nano 2008;2:873–878. [CrossRef]
[27] Ben-Ari ET. Nanoscale quantum dots hold promise for cancer applications. J Natl Cancer Inst 2003;95:502–504. [CrossRef]
[28] Hezinger AFE, Teßmar J, Göpferich A. Polymer coating of quantum dots: a powerful tool toward diagnostics and sensorics. Eur J Pharm Biopharm 2008;68:138–152. [CrossRef]
[29] Yong KT, Roy I, Swihart MT, Prasad PN. Multifunctional nanoparticles as biocompatible targeted probes for human cancer diagnosis and therapy. J Mater Chem 2009;19:4655–4672. [CrossRef]
[30] Smith AM, Dave S, Nie S, True L, Gao X. Multicolor quantum dots for molecular diagnostics of cancer. Expert Rev Mol Diagn 2006;6:231–244. [CrossRef]
[31] Zhang H, Yee D, Wang C. Quantum dots for cancer diagnosis and therapy: biological and clinical perspectives. Nanomedicine (Lond) 2008;3:83–91. [CrossRef]
[32] Smith AM, Duan H, Mohs AM, Nie S. Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv Drug Deliv Rev 2008;60:1226–1240. [CrossRef]
[33] Tada H, Higuchi H, Wanatabe TM, Ohuchi N. In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. Cancer Res 2007;67:1138–1144. [CrossRef]
[34] Shah BS, Clark PA, Moioli EK, Stroscio MA, Mao JJ. Labeling of mesenchymal stem cells by bioconjugated quantum dots. Nano Lett 2007;7:3071–3079. [CrossRef] [35] Yong KT, Ding H, Roy I, Law WC, Bergey EJ, Maitra A, et al. Imaging pancreatic cancer using bioconjugated InP quantum dots. ACS Nano 2009;3:502–510. [CrossRef]
[36] Fang M, Peng C, Pang DW, Li Y. Quantum dots for cancer research: current status, remaining issues, and future perspectives. Cancer Biol Med 2012;9:151.
[37] Khaledian S, Abdoli M, Fatahian R, Zahabi SS. Quantum dots in cancer cell imaging. In: Quantum Dots-Recent Advances, New Perspectives and Contemporary Applications. London: IntechOpen; 2023. [CrossRef]
[38] Liang Z, Khawar MB, Liang J, Sun H. Bio-conjugated quantum dots for cancer research: detection and imaging. Front Oncol 2021;11:749970. [CrossRef]
[39] Jaffar AF, Salman AM, Akram IN, Al Dergazly AA. Nonlinear properties and optical limiting of olive oil by using z-scan technique. Al- Nahrain University; 2012. [CrossRef]
[40] Salman AM, Salman AA, Al-Janabi A. Stable L-band multiwavelength erbium-doped fiber laser based on four-wave mixing using nickel nanofluid. Appl Opt 2019;58:6136–6143. [CrossRef]
[41] Xu P, Feng W, Wang M, Zhang L, Liang G, Jing A. New ultrasensitive sandwich-type immunoassay of dendritic tri-fan blade-like PdAuCu nanoparticles/amine-functionalized graphene oxide for label-free detection of carcinoembryonic antigen. Micromachines 2021;12. [CrossRef]
[42] Al-Ogaidi I, Aguilar ZP, Suri S, Gou H, Wu N. Dual detection of cancer biomarker CA125 using absorbance and electrochemical methods. Analyst 2013;138:5647–5653. [CrossRef]
[43] Li JJ, et al. Large-scale synthesis of nearly monodisperse CdSe/CdS core/shell nanocrystals using air-stable reagents via successive ion layer adsorption and reaction. J Am Chem Soc 2003;125:12567–12575. [CrossRef]
[44] Mongia SK, Rawlins ML, Owen WE, Roberts WL. Performance characteristics of seven automated CA125 assays. Am J Clin Pathol 2006;125:921–927. [CrossRef]

Details

Primary Language

English

Subjects

Clinical Sciences (Other)

Journal Section

Research Article

Authors

Marwah Al-ogaidi ^* This is me
0000-0002-5991-1162
Iraq

Nuha Nihad A. Aburahma This is me
0000-0003-4606-1004
Iraq

Ansam M. Salman This is me
0000-0002-8597-2305
Iraq

Haider Raad This is me
0000-0002-1124-1753
United States

Publication Date

December 9, 2024

Submission Date

September 4, 2023

Acceptance Date

January 2, 2024

Published in Issue

Year 2024 Volume: 42 Number: 6

IZ

https://izlik.org/JA36PU55LU

Cite

RIS / Bibtex

APA

Al-ogaidi, M., Nihad A. Aburahma, N., M. Salman, A., & Raad, H. (2024). Nanoscale detection of ovarian cancer biomarker. Sigma Journal of Engineering and Natural Sciences, 42(6), 1884-1891. https://izlik.org/JA36PU55LU

AMA

1.Al-ogaidi M, Nihad A. Aburahma N, M. Salman A, Raad H. Nanoscale detection of ovarian cancer biomarker. SIGMA. 2024;42(6):1884-1891. https://izlik.org/JA36PU55LU

Chicago

Al-ogaidi, Marwah, Nuha Nihad A. Aburahma, Ansam M. Salman, and Haider Raad. 2024. “Nanoscale Detection of Ovarian Cancer Biomarker”. Sigma Journal of Engineering and Natural Sciences 42 (6): 1884-91. https://izlik.org/JA36PU55LU.

EndNote

Al-ogaidi M, Nihad A. Aburahma N, M. Salman A, Raad H (December 1, 2024) Nanoscale detection of ovarian cancer biomarker. Sigma Journal of Engineering and Natural Sciences 42 6 1884–1891.

IEEE

[1]M. Al-ogaidi, N. Nihad A. Aburahma, A. M. Salman, and H. Raad, “Nanoscale detection of ovarian cancer biomarker”, SIGMA, vol. 42, no. 6, pp. 1884–1891, Dec. 2024, [Online]. Available: https://izlik.org/JA36PU55LU

ISNAD

Al-ogaidi, Marwah - Nihad A. Aburahma, Nuha - M. Salman, Ansam - Raad, Haider. “Nanoscale Detection of Ovarian Cancer Biomarker”. Sigma Journal of Engineering and Natural Sciences 42/6 (December 1, 2024): 1884-1891. https://izlik.org/JA36PU55LU.

JAMA

1.Al-ogaidi M, Nihad A. Aburahma N, M. Salman A, Raad H. Nanoscale detection of ovarian cancer biomarker. SIGMA. 2024;42:1884–1891.

MLA

Al-ogaidi, Marwah, et al. “Nanoscale Detection of Ovarian Cancer Biomarker”. Sigma Journal of Engineering and Natural Sciences, vol. 42, no. 6, Dec. 2024, pp. 1884-91, https://izlik.org/JA36PU55LU.

Vancouver

1.Marwah Al-ogaidi, Nuha Nihad A. Aburahma, Ansam M. Salman, Haider Raad. Nanoscale detection of ovarian cancer biomarker. SIGMA [Internet]. 2024 Dec. 1;42(6):1884-91. Available from: https://izlik.org/JA36PU55LU